•  

Success Stories

Bristol Myers Squibb Enters Agreement to Acquire Forbius

TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio. TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ... Read more